Literature DB >> 24662497

Outcome measures in randomized-controlled trials of neuropathic pain conditions: a systematic review of systematic reviews and recommendations for practice.

Poonam Mehta1, Leica Claydon, Paul Hendrick, Stanley Winser, G David Baxter.   

Abstract

OBJECTIVES: Neuropathic pain (NeP) is a prevalent, disabling, multidimensional condition with significant morbidity; however, there appears to be a variable approach in the use of outcome measures in NeP trials. A search of systematic reviews of interventional randomized-controlled trials for NeP was undertaken to investigate the range and types of outcome measures used to determine treatment effects.
METHODS: Keywords and MESH searches were conducted in 5 electronic databases from inception to January 31, 2012. Full-text English-language reviews based on various acute and chronic NeP conditions were included. Two independent reviewers screened papers for inclusion, extracted data, and assessed the quality of reviews. Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines were used to critically appraise the reviews.
RESULTS: A total of 46 studies were identified: the majority of reviews (n=28/46, 61%) scored well on the PRISMA (PRISMA scores of 20-27/27). Change in levels or intensity of pain were used by the majority of studies as the primary outcome measure in intervention studies (n=40/46 studies, 87%). Few studies used a functional outcome measure as either a primary or secondary outcome measure (n=7/46, 15% of studies). DISCUSSION: These results demonstrate that measures of pain are predominantly used in trials of NeP conditions and highlight the scant usage of functional outcome measures. The lack of standardization for the diagnostic criteria in NeP trials is also an issue that needs to be considered for future research and guideline development.

Entities:  

Mesh:

Year:  2015        PMID: 24662497     DOI: 10.1097/AJP.0000000000000088

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  4 in total

Review 1.  Clinical outcome assessment in clinical trials of chronic pain treatments.

Authors:  Kushang V Patel; Dagmar Amtmann; Mark P Jensen; Shannon M Smith; Christin Veasley; Dennis C Turk
Journal:  Pain Rep       Date:  2021-01-21

2.  The effect of a topical combination of clonidine and pentoxifylline on post-traumatic neuropathic pain patients: study protocol for a randomized, double-blind placebo-controlled trial.

Authors:  Oli Abate Fulas; André Laferrière; D Mark A Ware; Yoram Shir; Terence J Coderre
Journal:  Trials       Date:  2021-02-17       Impact factor: 2.279

3.  Evaluation of composite responder outcomes of pain intensity and physical function in neuropathic pain clinical trials: an ACTTION individual patient data analysis.

Authors:  Kushang V Patel; Robert Allen; Laurie Burke; John T Farrar; Jennifer S Gewandter; Ian Gilron; Nathaniel P Katz; John D Markman; Scott F Marshall; Malca Resnick; Andrew S C Rice; Michael C Rowbotham; Shannon M Smith; Geertrui F Vanhove; Ajay D Wasan; Shuyu Zhang; Robert H Dworkin; Dennis C Turk
Journal:  Pain       Date:  2018-11       Impact factor: 7.926

4.  Prediction of response to tapentadol in chronic low back pain.

Authors:  M Reimer; P Hüllemann; M Hukauf; T Keller; A Binder; J Gierthmühlen; R Baron
Journal:  Eur J Pain       Date:  2016-08-11       Impact factor: 3.931

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.